Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EO2401 + nivolumab in adrenocortical carcinoma and pheochromocytoma/paraganglioma
NCT04187404Phase 2Terminated
- Sponsor
- Enterome
- Start
- Jul 2020
- Primary completion
- Oct 2024
- Modality
- Prophylactic Vaccines, Peptides, Peptide-based Cancer Vaccines
- Countries
- 8
01
Overview
A Phase 2 trial of eo2401 in adrenocortical carcinoma (ACC), pheochromocytoma, Paraganglioma (PGL), sponsored by Enterome. Started Jul 2020; status: terminated.
02
Drugs
eo2401
03
Conditions
adrenocortical carcinoma (ACC)pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT04187404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04187404.